NCT03950843

A Clinical Trial to Evaluate the Efficacy and Safety of CKD-825 in Patients With Atrial Fibrillation

A Multi-center, Randomized, Double-blind, Placebo Control, Therapeutic Confirmatory, Phase III Trial to Evaluate the Efficacy and Safety of CKD-825 in Patients With Atrial Fibrillation

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 162 (estimated)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

to Evaluate the Efficacy and Safety of CKD-825 in Patients With Atrial Fibrillation

Detailed description

A Multi-center, Randomized, Double-blind, Placebo control, Therapeutic Confirmatory, Phase III Trial to Evaluate the Efficacy and Safety of CKD-825 in Patients With Atrial Fibrillation

Conditions

• Atrial Fibrillation

Interventions

Type	Name	Description
DRUG	CKD-825	* Dosage Form: capsule * Dosage: 3 types(low/medium/high dose) * Frequency: QD(once daily) administration
DRUG	Placebo oral capsule	Placebo of CKD-825 * Dosage Form: capsule * Dosage: NA * Frequency: QD administration

Timeline

• Start date: 2019-04-23
• Primary completion: 2021-09-01
• Completion: 2021-12-01
• First posted: 2019-05-15
• Last updated: 2019-05-15

Locations

1 site across 1 country: South Korea